Michelson Diagnostics is delighted to announce that it has received Korean Ministry of Food and Drug Safety, MFDS, (formerly the KFDA) approval for the VivoSight Dx Optical Coherence Tomography (OCT) system. VivoSight Dx is globally the most widely used OCT system for dermatological imaging, providing high-resolution, non-invasive images through the skin for a wide spectrum of clinical and research applications.
VivoSight Dx is being brought to the Korean market through Michelson’s Seoul-based local partner and distributor SnT Lab, Korea’s leading provider of skin imaging systems.
Bruce Lee, Executive Director, R&D Centre at SnT Lab, commented:
“This is an exciting development for dermatology in Korea. The availability of OCT imaging with VivoSight will address a large need for non-invasive quantitative analysis of skin function and structure in Korean cosmetics and skin health corporations, and academic centres.”
To learn more about VivoSight Dx OCT imaging in Korea, please contact Bruce Lee, firstname.lastname@example.org